Skip to main content
Erschienen in: Journal of General Internal Medicine 5/2009

01.05.2009 | Health Policy

Who Gets Disease Management?

verfasst von: Melinda Beeuwkes Buntin, PhD, Arvind K. Jain, MS, Soeren Mattke, MD, ScD, Nicole Lurie, MD, MSPH

Erschienen in: Journal of General Internal Medicine | Ausgabe 5/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

Disease management (DM) has been promoted to improve health outcomes and lower costs for patients with chronic disease. Unfortunately, most of the studies that support claims of DM’s success suffer from a number of biases, the most important of which is selection bias, or bias in the type of patients enrolling.

Objective

To quantify the differences between those who do and do not enroll in DM.

Design, Setting, and Participants

This was an observational study of the health care use, costs, and quality of care of 27,211 members of a large health insurer who were identified through claims as having asthma, diabetes, or congestive heart failure, were considered to be at high risk for incurring significant claims costs, and were eligible to join a disease management program involving health coaching.

Measurements

We used health coach call records to determine which patients participated in at least one coaching call and which refused to participate. We used claims data for the 12 months before the start of intervention to tabulate costs and utilization metrics. In addition, we calculated HEDIS quality scores for the year prior to the start of intervention.

Results

The patients who enrolled in the DM program differed significantly from those who did not on demographic, cost, utilization and quality parameters prior to enrollment. For example, compared to non-enrollees, diabetes enrollees had nine more prescriptions per year and higher HbA1c HEDIS scores (0.70 vs. 0.61, p < 0.001).

Conclusions

These findings illuminate the serious problem of selection into DM programs and suggest that the effectiveness levels found in prior evaluations using methodologies that don’t address this may be overstated.
Literatur
2.
Zurück zum Zitat Todd W, Nash D, eds. Disease Management: A Systems Approach to Improving Patient Outcomes. San Francisco: Jossey Bass: 2001. Todd W, Nash D, eds. Disease Management: A Systems Approach to Improving Patient Outcomes. San Francisco: Jossey Bass: 2001.
3.
Zurück zum Zitat Ellrodt G, Cook DJ, Lee J, Cho M, Hunt D, Weingarten S. Evidence-based disease management. JAMA. 1997;278:1687–92.PubMedCrossRef Ellrodt G, Cook DJ, Lee J, Cho M, Hunt D, Weingarten S. Evidence-based disease management. JAMA. 1997;278:1687–92.PubMedCrossRef
5.
Zurück zum Zitat Casalino LP. Disease management and the organization of physician practice. JAMA. 2005;293:485–8.PubMedCrossRef Casalino LP. Disease management and the organization of physician practice. JAMA. 2005;293:485–8.PubMedCrossRef
8.
Zurück zum Zitat Mattke S, Seid M, Ma S. Evidence for the impact of disease management: is $1 billion a year a good investment? Am J Managed Care. 2007;13(12):670–8. Mattke S, Seid M, Ma S. Evidence for the impact of disease management: is $1 billion a year a good investment? Am J Managed Care. 2007;13(12):670–8.
10.
Zurück zum Zitat Linden A, Roberts N. A user’s guide to the disease management literature: recommendations for reporting and assessing program outcomes. Am J Manag Care. 2005;11:113–20.PubMed Linden A, Roberts N. A user’s guide to the disease management literature: recommendations for reporting and assessing program outcomes. Am J Manag Care. 2005;11:113–20.PubMed
11.
Zurück zum Zitat Linden A, Adams J. Evaluating disease management programme effectiveness: an introduction to instrumental variables. J Eval Clin Pract. 2006;12:148–54.PubMedCrossRef Linden A, Adams J. Evaluating disease management programme effectiveness: an introduction to instrumental variables. J Eval Clin Pract. 2006;12:148–54.PubMedCrossRef
12.
Zurück zum Zitat Beaulieu N, Cutler D, Ho K, et al. The business care for diabetes disease management for managed care organizations. Forum for Health Economics and Policy. 2006;9(1). Beaulieu N, Cutler D, Ho K, et al. The business care for diabetes disease management for managed care organizations. Forum for Health Economics and Policy. 2006;9(1).
13.
Zurück zum Zitat Fremont AM, Bierman A, Wickstrom SL, et al. Use of geocoding in managed care settings to identify quality disparities. Health Aff. 2005;24:516–26.CrossRef Fremont AM, Bierman A, Wickstrom SL, et al. Use of geocoding in managed care settings to identify quality disparities. Health Aff. 2005;24:516–26.CrossRef
14.
Zurück zum Zitat Elliott MN, Fremont A, Morrison PA, Pantoja P, Abrahamse A, Lurie N. A new method for estimating racial/ethnic disparities where administrative records lack self-reported race/ethnicity. Health Serv Res. 2008;43(5p1):1722–36.CrossRef Elliott MN, Fremont A, Morrison PA, Pantoja P, Abrahamse A, Lurie N. A new method for estimating racial/ethnic disparities where administrative records lack self-reported race/ethnicity. Health Serv Res. 2008;43(5p1):1722–36.CrossRef
15.
Zurück zum Zitat Abrahamse AP, Morrison A, Bolton NM. Surname analysis for estimating local concentration of Hispanics and Asians. Popul Res Policy Rev. 1994;13:383–98.CrossRef Abrahamse AP, Morrison A, Bolton NM. Surname analysis for estimating local concentration of Hispanics and Asians. Popul Res Policy Rev. 1994;13:383–98.CrossRef
17.
Zurück zum Zitat Von Korff M, Gruman J, Schaefer J, Curry S, Wagner E. Collaborative management of chronic illness. Ann Intern Med. 1997;127(12):1097–102. Von Korff M, Gruman J, Schaefer J, Curry S, Wagner E. Collaborative management of chronic illness. Ann Intern Med. 1997;127(12):1097–102.
18.
Zurück zum Zitat Linden A, Adams JL, Roberts N. Strengthening the case for disease management effectiveness: un-hiding the hidden bias. J Eval Clin Pract. 2006b;12:140–7.PubMedCrossRef Linden A, Adams JL, Roberts N. Strengthening the case for disease management effectiveness: un-hiding the hidden bias. J Eval Clin Pract. 2006b;12:140–7.PubMedCrossRef
19.
Zurück zum Zitat Linden A, Adams JL, Roberts N. Using propensity scores to construct comparable control groups for disease management program evaluation. Dis Manag Health Outcomes. 2006c;13:107–15.CrossRef Linden A, Adams JL, Roberts N. Using propensity scores to construct comparable control groups for disease management program evaluation. Dis Manag Health Outcomes. 2006c;13:107–15.CrossRef
20.
Zurück zum Zitat DMAA. Outcomes Guidelines Report Volume II. Washington, DC; 2007. DMAA. Outcomes Guidelines Report Volume II. Washington, DC; 2007.
Metadaten
Titel
Who Gets Disease Management?
verfasst von
Melinda Beeuwkes Buntin, PhD
Arvind K. Jain, MS
Soeren Mattke, MD, ScD
Nicole Lurie, MD, MSPH
Publikationsdatum
01.05.2009
Verlag
Springer-Verlag
Erschienen in
Journal of General Internal Medicine / Ausgabe 5/2009
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-009-0950-8

Weitere Artikel der Ausgabe 5/2009

Journal of General Internal Medicine 5/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.